Ionis Pharmaceuticals Says Topline Results From The Pivotal Study Of Zilganersen For Alexander Disease Showed Statistically Significant And Clinically Meaningful Stabilization On The Primary Endpoint Of Gait Speed Compared To Control
Author: Benzinga Newsdesk | September 22, 2025 07:07am
First and only investigational medicine to demonstrate a clinically meaningful and disease-modifying impact on this rare, often fatal neurological condition.